An in vitro method of predicting a response for patients, having neurodevelopmental, neurological or neuropsychiatric disorders, if treated with a compound, targeting the glutamatergic pathway, comprises the steps i) determining the protein concentration of one, two, three, four five or six members of the complement factor H family or a mixture or a combination thereof in a sample of a patient and ii) comparing the protein concentration determined in step i) to a value representative of the protein concentration of one, two three, four, five or six members of complement factor H family in patients, having neurodevelopmental, neurological or neuropsychiatric disorders. A higher protein concentration of one, two three, four five or six members from complement factor H family in the sample of the patient having neurodevelopmental, neurological or neuropsychiatric disorders is indicative for a patient who will derive clinical benefit from this treatment. The method further comprises iii) selecting this treatment for patients having neurodevelopmental, neurological or neuropsychiatric disorders. Also disclosed is an in vitro method of predicting a response for patients, having neurodevelopmental, neurological or neuropsychiatric disorders, if treated with a compound targeting the glutamatergic pathway, wherein the protein concentration of individual members of the complement factor H family or a mixture or a combination thereof are determined by measuring genetic variants of complement factor H family members. Complement factor H family members are useful as predictive markers for patients who are treated with compounds targeting the glutamatergic pathway or for patients who are treated with a glycine reuptake inhibitor.
A method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders